Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.

ABSTRACT:

Background and aims

The heterogeneous nature of breast cancer can make decisions on adjuvant chemotherapy following surgical resection challenging. Oncotype DX is a validated gene expression profiling test that predicts the likelihood of adjuvant chemotherapy benefit in early-stage breast cancer. The aim of this study is to determine the costs of chemotherapy in private hospitals in France, and evaluate the cost-effectiveness of Oncotype DX from national insurance and societal perspectives.

Methods

A multicenter study was conducted in seven French private hospitals, capturing retrospective data from 106 patient files. Cost estimates were used in conjunction with a published Markov model to assess the cost-effectiveness of using Oncotype DX to inform chemotherapy decision mak

SUBMITTER: Katz G 

PROVIDER: S-EPMC4472722 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature